Contact Us | Log In
Search
Sensex: 33324.5 -18.30 Gold: Rs.29678.00
Nifty: 10281 -2.60 Silver: Rs.39919.00
You are here: IndiaNotes >> Companies
Alembic Pharmaceuticals Ltd.
BSE : 533573 | NSE : APLLTDEQ | ISIN : INE901L01018 | Sector : Pharmaceuticals and health care
BSE : 515.95 +2.35 (0.46%)
NSE : 517.95 +1.85 (0.36%)
Latest Quote
BSE: 20th Nov 2017
Open Price 519.95
High Price 520.00
Low Price 513.05
Prev. Close 513.60
Volume 78
52 Wk High 709.30
52 Wk Low 469.75
NSE: 20th Nov 2017
Open Price 515.95
High Price 520.40
Low Price 507.40
Prev. Close 516.10
Volume 3,623
52 Wk High 673.70
52 Wk Low 469.85
What Are Analysts Saying for Alembic-Pharmaceuticals-Ltd
Alembic Pharma: Business remains under pressure - assign SHORT
Equirus Securities | 14 Nov, 2017
Alembic Pharma’s (ALPM) 2QFY18 sales (-10% yoy to Rs 7.9bn) fell short of estimates due to below-expected US and domestic sales. However, EBITDA/PAT at Rs 1.8bn/1.2bn came in ahead of EE mainly on acc...
Alembic Pharmaceuticals: Opportunities abound for future market growth
SPA Securities | 14 Sep, 2017
The company is aggressively investing in R&D and expansion, especially to build a strong US foothold. This includes a foray into niche areas like oncology, injectables, derma, etc....
Alembic Pharma Q4FY17: Book partial profits and 'hold' on the remaining stock
Nirmal Bang | 05 May, 2017
Nirmal Bang believe that the company has successfully crafted a niche for itself in US markets and likely to remain a focus player. They recommend investors to book partial profits and HOLD on the rem...
Q4FY16 Results Review: Indian pharma companies; Growth drivers remains intact
IndiaNivesh | 08 Jun, 2016
Indian pharma companies under our coverage has shown 37% y‐y growth in adjusted PAT on aggregate basis. The outperformers for the quarter were GNP, JBCP, LPC, SLPA, SUNP and TRP who delivered be...
Alembic Pharma: Q4FY16 Results below expectations; Hold
Nirmal Bang | 02 May, 2016
Alembic Pharma Limited (APL) posted results below than expectations due to lower Abilify sales and high R&D expenses. We believe the current rich valuations factor in much of the upside and considerin...
View all
Key Fundamentals
Market Cap (Rs. Cr.): ......................... 9,764.18
EPS - TTM (Rs.): ......................... 22.84
P/E Ratio (x): ......................... 22.67
Facevalue (Rs): ......................... 0.00
Latest Dividend (%): ......................... 10
Dividend Yield (%): ......................... 0.77
Book Value/Share (Rs.): ......................... 99.05
P/B Ratio (x): ......................... 5.23
Quick Links
* The links below will re-direct you to www.indianotes.com
  • Peer Comparison
  • Financials